Drugs / PG11047
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00293488 | Jan 2006 → Sep 2008 | lymphoma | Progen Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00705653 | Mar 2005 → Aug 2009 | cancer | Progen Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG11047 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00293488 ↗ |
| Known as | CGC-11047 | “Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors” NCT00705653 ↗ |
| Modality | Small molecule | “polyamine analog PG-11047” PMID 32447421 ↗ May 2020 |
| Route | Intravenous | “administered as a 30-minute IV infusion” NCT00293488 ↗ |